analysi
human
monoclon
antibodi
mab
develop
influenza
infect
donor
enorm
contribut
identif
neutral
sensit
epitop
influenza
viru
ha
protein
crucial
target
neutral
antibodi
monoclon
level
ab
bind
ha
abl
neutral
viru
studi
eight
pdm
seroposit
patient
within
age
rang
year
median
year
recruit
two
antiha
mab
secret
stabl
clone
establish
optim
condit
peripher
blood
mononuclear
cell
pbmc
volunt
antibodi
effici
neutral
homolog
laboratori
isol
strain
pandem
viru
well
refer
strain
studi
suggest
antiha
antibodi
deriv
infect
indian
patient
display
neutral
potenti
pdm
viru
first
ever
studi
gener
mab
pandem
influenza
viru
involv
immun
repertoir
indian
patient
molecular
character
target
region
help
identifi
potenti
immunogen
indian
pandem
isol
confer
protect
immun
viru
influenza
viru
member
orthomyxovirida
famili
one
main
caus
preval
infect
respiratori
tract
human
suscept
influenza
ill
common
immunolog
naiv
infant
immunocompromis
individu
elderli
virul
influenza
viru
easi
spread
aerosol
frequent
chang
viral
antigen
antigen
drift
antigen
shift
enabl
escap
protect
immun
influenza
infect
human
selflimit
viru
known
caus
substanti
mortal
morbid
worldwid
devast
influenza
pandem
global
mortal
reach
million
individu
one
year
stark
remind
pandem
popul
consid
fittest
vulner
recent
pandem
despit
intens
effort
threat
influenza
persist
mani
limit
use
exist
vaccin
antivir
therapi
protect
provid
vaccin
contain
kill
recombin
viral
glycoprotein
weak
may
last
littl
month
moreov
vaccin
efficaci
immunocompromis
elderli
individu
vaccin
formul
annual
exist
year
vaccin
may
provid
protect
newli
emerg
strain
current
four
antivir
drug
approv
use
influenza
viru
use
restrict
due
possibl
side
effect
rapid
emerg
resist
strain
recent
year
henc
develop
new
therapeut
target
strategi
control
pandem
season
influenza
viru
infect
human
urgent
need
passiv
immunotherapi
influenza
report
sinc
influenza
pandem
convalesc
sera
use
treat
patient
howev
use
convalesc
plasma
larg
replac
monoclon
antibodi
prepar
owe
recent
advanc
monoclon
antibodi
engin
sever
report
antibodi
therapi
use
polyclon
monoclon
antibodi
use
effect
prophylaxi
varicella
hepat
hepat
b
rabi
respiratori
syncyti
viru
infect
use
human
mab
human
mab
key
epitop
infecti
pathogen
may
help
defin
humor
respons
signific
therapeut
potenti
use
human
mab
may
also
lead
effect
post
exposur
prophylaxi
includ
use
intranas
viral
diseas
human
monoclon
antibodi
technolog
seen
variou
advanc
recent
like
use
epstein
barr
viru
ebv
transform
human
b
cell
develop
sever
new
heteromyeloma
cell
line
cpg
oligonucleotid
enhanc
effici
b
cell
transform
studi
gener
strongli
neutral
novel
human
monoclon
antibodi
select
immun
repertoir
influenza
infect
seroposit
patient
gener
two
stabl
monoclon
antibodi
secret
fusion
clone
produc
antibodi
specif
viru
investig
vivo
prophylact
therapeut
efficaci
monoclon
antibodi
influenza
viru
infect
vivo
model
studi
support
fact
fulli
human
mab
neutral
activ
success
gener
peripher
blood
convalesc
patient
optim
condit
madin
darbi
canin
kidney
mdck
cell
procur
nation
centr
cell
scienc
ncc
pune
india
ebv
transform
marmoset
leukocyt
cell
line
kind
gift
dr
rahul
pal
nii
delhi
human
mous
heteromyeloma
provid
dr
lisa
cavacini
beth
israel
deaco
medic
centr
boston
usa
pandem
viru
refer
strain
procur
victoria
infecti
diseas
refer
laboratori
vidrl
australia
eight
pdm
seroposit
patient
male
femal
within
age
rang
year
median
year
recruit
studi
rna
isol
nasal
throat
swab
sampl
influenza
viru
infect
detect
real
time
rt
pcr
volunt
low
ct
cycl
threshold
valu
influenza
approxim
week
onset
diseas
ml
blood
sampl
collect
heparan
vacutain
donor
ml
plasma
sampl
collect
sampl
store
serolog
examin
remain
blood
use
pbmc
isol
plasma
sampl
treat
receptor
destroy
enzym
rde
destruct
nonspecif
inhibitor
serial
two
fold
dilut
plasma
sampl
prepar
pb
microtit
plateth
plasma
sampl
dilut
ad
equal
volum
unit
plate
cover
incub
room
temperatur
rt
min
content
plate
mix
gentli
agit
plate
guinea
pig
rbc
ad
well
plate
cover
incub
rt
min
hai
titr
highest
dilut
serum
show
hemagglutin
activ
monoclon
antibodi
gener
pbmc
infect
patient
method
per
gorni
minor
modif
mononuclear
cell
isol
blood
seroposit
patient
densiti
gradient
centrifug
resuspend
ebv
transform
medium
cultur
supernat
dilut
complet
medium
rpmi
fc
concentr
x
cellsml
presenc
cpg
cultur
overnight
three
week
cultur
prolifer
transform
coloni
b
lymphocyt
observ
use
invert
microscop
posit
clone
screen
microneutr
expand
tissu
cultur
flask
posit
clone
fuse
ratio
cell
line
ad
ml
warm
pegdmso
solut
dropwis
min
cell
cultur
supernat
stabl
clone
collect
monoclon
antibodi
subsequ
purifi
affin
chromatographi
protein
g
column
sigma
aldrich
usa
madin
darbi
canin
kidney
mdck
cell
grown
well
tissu
cultur
plate
densiti
x
cell
per
well
infect
unit
viru
h
infect
cell
fix
aceton
methanol
min
follow
permeabil
triton
x
fix
cell
block
bsa
pb
h
wash
twice
pb
monoclon
antibodi
ad
concentr
plate
incub
plate
wash
thrice
pb
bound
antibodi
detect
fitc
label
goat
antihuman
igg
observ
immunofluoresc
microscop
hemagglutin
inhibit
assay
purifi
monoclon
antibodi
perform
end
point
dilut
method
two
fold
serial
dilut
purifi
monoclon
antibodi
taken
maximum
concentr
hai
titer
express
lowest
concentr
antibodi
complet
inhibit
unit
pandem
viru
microneutr
assay
purifi
antibodi
perform
end
point
dilut
method
briefli
two
fold
serial
dilut
antibodi
prepar
pb
start
highest
dilut
well
tissu
cultur
plate
pandem
isol
well
refer
strain
incub
equal
volum
antibodi
h
mdck
cell
x
cellsml
ad
well
plate
incub
day
examin
cpe
residu
infect
test
four
well
per
dilut
neutral
titer
determin
lowest
concentr
antibodi
infect
respect
viru
mdck
cell
complet
neutral
well
infect
identifi
presenc
cytopath
effect
day
titer
calcul
reedmuench
method
infect
cell
lysat
first
resolv
sdspage
transfer
pvdf
membran
use
transblot
sd
semidri
transfer
cell
biorad
laboratori
ca
usa
membran
block
nonfat
milk
tbst
h
room
temperatur
wash
thrice
tbst
blot
cut
strip
denatur
antigen
probe
incub
strip
singl
purifi
monoclon
ab
concentr
antihuman
igg
taken
neg
control
strip
wash
thoroughli
tbst
three
time
min
follow
incub
dilut
horseradish
peroxidas
hrp
conjug
goat
antihuman
igg
secondari
antibodi
dilut
milktbst
h
room
temperatur
wash
immunoreact
band
visual
addit
pb
contain
mgml
dab
sigma
aldrich
usa
evalu
degre
protect
monoclon
antibodi
week
old
femal
balbc
mice
per
group
intraperiton
inject
purifi
monoclon
antibodi
three
differ
concentr
pre
h
h
post
h
h
post
challeng
x
pfu
viru
mice
monitor
daili
sick
weight
loss
death
day
signific
differ
mean
determin
student
test
use
graph
pad
prism
softwar
version
san
diego
ca
usa
result
present
mean
sd
plasma
sampl
donor
show
serolog
reactiv
ha
refer
pandem
strain
evid
hemagglutin
inhibit
assay
show
titer
individu
titer
plasma
sampl
mention
tabl
pbmc
eight
seroposit
volunt
transform
ebv
supernat
transform
coloni
screen
microneutr
assay
influenza
viru
specif
antibodi
tabl
ii
posit
clone
fuse
heteromyeloma
cell
fusion
two
stabl
fusion
clone
secret
neutral
monoclon
antibodi
pandem
viru
establish
pbmc
patient
success
transform
ebv
mean
pbmc
isol
patient
million
per
individu
rang
pbmc
plate
well
tissu
cultur
plate
cell
per
well
approxim
well
posit
neutral
antibodi
autologu
viru
clone
clone
deriv
separ
donor
donor
donor
respect
transform
coloni
lost
reactiv
subsequ
round
screen
due
possibl
outgrowth
nonsecretor
instabl
antibodi
gener
mab
purifi
affin
chromatographi
protein
g
column
monoclon
antibodi
analyz
vitro
seri
bound
pandem
viru
elisa
dose
depend
manner
show
lesser
bind
compar
antibodi
figur
similar
result
obtain
two
monoclon
antibodi
test
bind
ha
panel
virus
select
hai
assay
mab
show
bind
refer
pandem
strain
well
laboratori
isol
show
bind
viru
test
indic
hai
activ
detect
concentr
test
immunofluoresc
data
support
find
bound
strongli
influenza
viru
infect
mdck
cell
compar
mab
figur
gel
run
denatur
condit
allow
ha
protein
denatur
antibodi
react
denatur
viral
protein
evid
band
figur
contrast
antibodi
show
bind
activ
denatur
may
hypothesis
show
bind
region
denatur
ha
protein
might
recogn
conform
epitop
mice
treat
grade
dose
two
mab
pre
h
post
h
post
infect
respect
strain
influenza
virus
mention
method
section
antibodi
evalu
prophylact
therapeut
efficaci
assess
morbid
loss
weight
mortal
viral
load
histopatholog
examin
lung
surviv
weight
loss
experi
suggest
mab
achiev
consider
protect
dose
administ
prophylact
therapeut
tabl
iv
mab
effect
dose
viral
load
analysi
perform
subgroup
pre
h
post
challeng
mab
lung
viru
titer
treat
mice
confirm
upon
treatment
mab
viru
titer
consider
reduc
lung
tabl
v
product
human
monoclon
antibodi
much
complex
procedur
product
murin
monoclon
antibodi
scarciti
antibodi
produc
cell
peripher
blood
difficulti
obtain
blood
natur
infect
patient
right
time
one
major
concern
moreov
ebv
transform
b
cell
hard
grow
secret
low
amount
antibodi
instabl
antibodi
product
epsteinbarr
viru
transform
cell
fuse
cell
anoth
concern
factor
result
decreas
fusion
effici
chanc
obtain
human
hybridoma
antigen
interest
order
human
hybridoma
technolog
base
two
main
method
fusion
ab
produc
b
cell
myeloma
cell
transform
b
lymphocyt
ebv
combin
method
prove
benefici
either
alon
studi
report
gener
two
stabl
fusion
clone
secret
monoclon
antibodi
influenza
virus
condit
ebv
transform
fusion
heteromyeloma
cell
line
optimis
overcom
limit
current
technolog
convalesc
phase
plasma
eight
influenza
posit
patient
screen
influenza
viru
specif
antibodi
serumplasma
antibodi
titr
critic
factor
gener
monoclon
antibodi
pbmc
pbmc
ebv
transform
presenc
cpg
oligonucleotid
report
increas
rate
ebv
transform
overal
transform
effici
achiev
cell
posit
antibodi
pandem
viru
fuse
cell
best
antibodi
secret
hybrid
clone
one
cell
well
ensur
monoclon
antibodi
gener
stabl
fusion
clone
secret
mab
show
neutral
vitro
well
vivo
condit
monoclon
antibodi
show
maximum
bind
vitro
assay
neutral
human
isol
pandem
strain
well
refer
strain
lowest
concentr
compar
antibodi
mab
show
lesser
bind
elisa
immunofluoresc
assay
although
show
hai
neutral
activ
higher
concentr
compar
antibodi
western
blot
analysi
monoclon
antibodi
reveal
bound
region
denatur
ha
protein
show
bind
region
denatur
ha
protein
henc
hypothesis
may
bind
conform
epitop
region
howev
bind
properti
need
investig
confirm
hypothesi
monoclon
antibodi
show
bind
season
viru
hai
activ
determin
refer
strain
avail
laboratori
pick
randomli
hai
studi
studi
regard
map
epitop
antibodi
reveal
inform
whether
exhibit
cross
reactiv
influenza
viru
strain
antibodi
howev
show
compar
neutral
hai
activ
laboratori
isol
pandem
viru
refer
strain
data
reflect
fact
indian
pandem
isol
shown
much
deviat
prototyp
pandem
strain
term
antibodi
bind
site
prophylact
therapeut
efficaci
antibodi
determin
mice
antibodi
treatment
given
h
h
h
challeng
pandem
strain
vivo
result
consist
vitro
studi
antibodi
abl
consider
protect
mice
lethal
influenza
challeng
antibodi
protect
prophylact
could
achiev
protect
term
surviv
assay
achiev
surviv
rate
antibodi
less
protect
h
post
infect
compar
h
fact
support
surviv
assay
weight
loss
percentag
histopatholog
examin
lung
done
group
mice
treat
therapeut
hisptopatholog
data
support
surviv
morbid
result
lung
mice
given
therapeut
dose
antibodi
show
consider
less
sign
alveolar
damag
neutrophil
infiltr
result
viru
infect
antibodi
may
employ
therapeut
agent
least
h
influenza
infect
indic
studi
mice
best
knowledg
antibodi
first
fulli
human
monoclon
antibodi
gener
immun
repertoir
indian
patient
infect
viru
molecular
character
epitop
indian
pandem
isol
reveal
inform
crossprotect
bind
characterist
strength
approach
antibodi
gener
lie
fact
use
human
immun
repertoir
rather
anim
antibodi
gener
respons
natur
infect
influenza
viru
sinc
antibodi
origin
human
self
reactiv
selfantigen
minimis
comparison
antibodi
gener
mice
techniqu
phage
display
